^
    Back
    Association details:
    Biomarker:EBF1-PDGFRB fusion
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Haematologica
    Title:

    Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion

    Excerpt:
    ...a case of refractory B-cell precursor ALL (BCP-ALL) where the identification of a genomic alteration activating kinase signaling, the EBF1-PDGFRB fusion, allowed the patient to benefit from early introduction of imatinib treatment, with subsequent cytological remission and profound MRD response.
    DOI:
    10.3324%2Fhaematol.2013.095372
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Pediatr Hematol Oncol
    Title:

    B-Cell Precursor-Acute Lymphoblastic Leukemia With EBF1-PDGFRB Fusion Treated With Hematopoietic Stem Cell Transplantation and Imatinib: A Case Report and Literature Review

    Excerpt:
    Since further investigation revealed EBF1-PDGFRB fusion, her condition was treated as BCR-ABL1-like acute lymphoblastic leukemia. She was started on a tyrosine kinase inhibitor, imatinib, and chemotherapy and underwent umbilical cord blood transplantation following reduced intensity conditioning. She has remained in complete remission for 36 months after cord blood transplantation.
    DOI:
    10.1097/MPH.0000000000001743
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Clin Oncol
    Title:

    Tyrosine Kinase Inhibitor Therapy Induces Remission in a Patient With Refractory EBF1-PDGFRB–Positive Acute Lymphoblastic Leukemia

    Excerpt:
    ...we present a child with EBF1-PDGFRB–positive ALL whose disease was refractory to conventional induction chemotherapy but who responded to the addition of imatinib to remission induction therapy, highlighting the potential for TKI therapy…
    DOI:
    10.1200/JCO.2012.47.6770
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Cell
    Title:

    Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia

    Excerpt:
    ...a xenograft model of NUP214-ABL1 ALL responded to dasatinib up to 8 weeks of treatment (Figure 7D)...Together, these data indicate that EBF1-PDGFRB, BCR-JAK2, NUP214-ABL1 fusions and sequence mutations in IL7R/SH2B3 are transforming, and represent excellent candidates for therapy with currently available TKIs.
    DOI:
    https://dx.doi.org/10.1016%2Fj.ccr.2012.06.005